Alan E. Berger
YOU?
Author Swipe
View article: Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy
Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy Open
Background Gastric carcinomas (GC) are aggressive malignancies, and only ~15% of patients respond to anti-programmed cell death (ligand) 1 (PD-(L)1) monotherapy. However, Epstein-Barr virus (EBV)-associated GCs (~5–10% of GCs) often harbor…
View article: Serum-deprivation response of ARPE-19 cells; expression patterns relevant to age-related macular degeneration
Serum-deprivation response of ARPE-19 cells; expression patterns relevant to age-related macular degeneration Open
ARPE-19 cells are derived from adult human retinal pigment epithelium (RPE). The response of these cells to the stress of serum deprivation mimics some important processes relevant to age-related macular degeneration (AMD). Here we extend …
View article: Conditions under which a natural iterative method for calculating the orientation distribution of rodlike particles decreases the free energy at each step
Conditions under which a natural iterative method for calculating the orientation distribution of rodlike particles decreases the free energy at each step Open
For physically meaningful particle interactions, a natural iteration of the orientation distribution function decreases the free energy, F, at each step and, in practice, converges at a local free energy minimum.
View article: Serum-deprivation response of ARPE-19 cells; expression patterns relevant to age-related macular degeneration
Serum-deprivation response of ARPE-19 cells; expression patterns relevant to age-related macular degeneration Open
ARPE-19 cells are derived from adult human retinal pigment epithelium (RPE). The response of these cells to the stress of serum deprivation mimics some important processes relevant to age-related macular degeneration (AMD). Here we extend …
View article: Supplementary Tables S1 through S3 from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
Supplementary Tables S1 through S3 from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma Open
Supplementary Table S1: PD-L1+ RCC specimens used in this study. Supplementary Table S2: Genes differentially expressed in RCC based on whole genome microarray analysis, in patients responding or not to anti-PD-1 therapy (234 probe sets co…
View article: Data from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
Data from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma Open
Pretreatment tumor PD-L1 expression has been shown to correlate with response to anti–PD-1/PD-L1 therapies. Yet, most patients with PD-L1+ tumors do not respond to treatment. The current study was undertaken to investigate mechanisms under…
View article: Supplementary Tables S1 through S3 from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
Supplementary Tables S1 through S3 from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma Open
Supplementary Table S1: PD-L1+ RCC specimens used in this study. Supplementary Table S2: Genes differentially expressed in RCC based on whole genome microarray analysis, in patients responding or not to anti-PD-1 therapy (234 probe sets co…
View article: Data from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
Data from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma Open
Pretreatment tumor PD-L1 expression has been shown to correlate with response to anti–PD-1/PD-L1 therapies. Yet, most patients with PD-L1+ tumors do not respond to treatment. The current study was undertaken to investigate mechanisms under…
View article: Supplementary Materials and Methods from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
Supplementary Materials and Methods from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma Open
Supplementary Materials and Methods
View article: Supplementary Figures S1 through S4 from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
Supplementary Figures S1 through S4 from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma Open
Figure S1: Extraction of paraffin-embedded PD-L1+ RCC tissues for RNA isolation. Figure S2: Molecules previously found to be up-regulated in PD-L1+ vs. PD-L1(-) melanomas are not differentially expressed in PD-L1+ RCCs from patients with d…
View article: Supplementary Figures S1 through S4 from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
Supplementary Figures S1 through S4 from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma Open
Figure S1: Extraction of paraffin-embedded PD-L1+ RCC tissues for RNA isolation. Figure S2: Molecules previously found to be up-regulated in PD-L1+ vs. PD-L1(-) melanomas are not differentially expressed in PD-L1+ RCCs from patients with d…
View article: Supplementary Materials and Methods from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
Supplementary Materials and Methods from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma Open
Supplementary Materials and Methods
View article: Supplementary Table S2 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Supplementary Table S2 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade Open
Supplementary Table S2: 1660 Illumina probes up-regulated at least 2-fold in PD-L1+ melanomas
View article: Supplementary Methods from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Supplementary Methods from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy Open
Supplementary methods
View article: Supplementary Table S2 from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Supplementary Table S2 from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy Open
Functionally annotated gene categories from DAVID analysis of Illumina probes differentially expressed between regressing vs. progressing melanoma metastases
View article: Data from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Data from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy Open
Purpose: To explore factors associated with response and resistance to anti–PD-1 therapy, we analyzed multiple disease sites at autopsy in a patient with widely metastatic melanoma who had a heterogeneous response.Materials and Methods: Tw…
View article: Supplementary Figures S1, S2A, S2B, S3, S4A, S4B from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Supplementary Figures S1, S2A, S2B, S3, S4A, S4B from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy Open
Supplementary figures
View article: Supplementary Table S2 from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Supplementary Table S2 from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy Open
Functionally annotated gene categories from DAVID analysis of Illumina probes differentially expressed between regressing vs. progressing melanoma metastases
View article: Supplementary Table S1, Supplementary Table S3, Supplementary Table S5 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Supplementary Table S1, Supplementary Table S3, Supplementary Table S5 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade Open
Supplementary Table S1, Supplementary Table S3, Supplementary Table S5. Supplementary Table S1: Genes selected for multiplex qRT-PCR array Supplementary Table S3: Functionally annotated gene categories from DAVID analysis of whole genome m…
View article: Data from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Data from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade Open
Purpose: Blocking the immunosuppressive PD-1/PD-L1 pathway has antitumor activity in multiple cancer types, and PD-L1 expression on tumor cells and infiltrating myeloid cells correlates with the likelihood of response. We previously found …
View article: Data from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Data from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy Open
Purpose: To explore factors associated with response and resistance to anti–PD-1 therapy, we analyzed multiple disease sites at autopsy in a patient with widely metastatic melanoma who had a heterogeneous response.Materials and Methods: Tw…
View article: Supplementary Figures 1 - 3 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Supplementary Figures 1 - 3 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade Open
Figure S1, Figure S2, Figure S3. Supplementary Figure S1: Overlay of PD-L1 and LAG-3 IHC demonstrates close geographic association of these cell-surface markers in a melanoma lymph node metastasis. Supplementary Figure S2: Comparison of im…
View article: Supplementary Table S1, Supplementary Table S3, Supplementary Table S5 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Supplementary Table S1, Supplementary Table S3, Supplementary Table S5 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade Open
Supplementary Table S1, Supplementary Table S3, Supplementary Table S5. Supplementary Table S1: Genes selected for multiplex qRT-PCR array Supplementary Table S3: Functionally annotated gene categories from DAVID analysis of whole genome m…
View article: Supplementary Methods from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Supplementary Methods from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy Open
Supplementary methods
View article: Supplementary Table S2 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Supplementary Table S2 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade Open
Supplementary Table S2: 1660 Illumina probes up-regulated at least 2-fold in PD-L1+ melanomas
View article: Supplementary methods from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Supplementary methods from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade Open
Supplementary methods
View article: Data from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Data from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade Open
Purpose: Blocking the immunosuppressive PD-1/PD-L1 pathway has antitumor activity in multiple cancer types, and PD-L1 expression on tumor cells and infiltrating myeloid cells correlates with the likelihood of response. We previously found …
View article: Supplementary methods from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Supplementary methods from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade Open
Supplementary methods
View article: Supplementary Table S4 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Supplementary Table S4 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade Open
Supplementary Table S4: DAVID clustering of 1660 Illumina probes up-regulated at least 2-fold in PD-L1+ melanomas